What Is the First-Line Treatment of Primary Central Nervous System Lymphoma?
Primary central nervous system lymphoma (PCNSL) is a rare, aggressive lymphoma arising within the brain, spinal cord, eyes, or leptomeninges without systemic disease. Because the blood-brain barrier restricts drug delivery, first-line treatment must rely on agents that can penetrate the CNS at therapeutically meaningful concentrations.
First-Line Treatment Approach
Induction is built around a high-dose methotrexate (HD-MTX)-based immunochemotherapy regimen. HD-MTX is paired with additional active agents selected specifically for their ability to cross the blood-brain barrier — the combination and the specific multi-drug regimen are determined by protocol-defined criteria.
Full regimen composition, agent selection, sequencing, and treatment algorithm are available in the complete protocol below.
References
DOI: 10.1093/neuonc/noac196
- HD-MTX is the drug of choice in PCNSL and chemotherapy should include MTX at HD (≥3 g/m2) both to cross the BBB and yield cytotoxic levels in the CSF.
- Chemotherapeutic agents to combine with HD MTX should be selected among active drugs known to cross the blood-brain-barrier, such as HD cytarabine and combinations used in large and/or randomized prospective trials have to be preferred (Level B).
- Most combinations addressed in large clinical trials include HD-MTX associated with an alkylating agent (procarbazine, carmustine, temozolomide, and thiotepa) (Level B).
- Patients receiving the most intensive induction regimen, consisting of HD-MTX, Ara-C, rituximab, and thiotepa (the MATRix regimen), showed a significantly higher CR rate (49%) in comparison to 23% in the least intensive regimen, consisting of HD-MTX and Ara-C, (P = .0007) with a 2-year OS of 69% and 42% respectively.
View source ↗